<DOC>
	<DOCNO>NCT00708591</DOCNO>
	<brief_summary>To determine maximum tolerate dose , observed toxicity , dose limit toxicity , antitumor response rapamycin plus ketoconazole patient advance cancer .</brief_summary>
	<brief_title>Study Rapamycin Plus Ketoconazole Advanced Cancers</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . Patients hematologic malignancy ( lymphoma , multiple myeloma CLL ) eligible participate phase Ib portion trial At least 4 week since prior chemotherapy radiation therapy ( 6 week last regimen include BCNU mitomycin C ) . Age &gt; 18 year . ECOG performance status less equal 2 Life expectancy 3 month . Normal organ marrow function define : Hemoglobin ≥ 10 g/dl Leukocytes ≥ 3,000/µL WBC ≥ 1,500/µL patient hematologic malignancy Absolute neutrophil count ≥ 1,500/µL ( ≥ 1,000/µL patient hematologic malignancy ) Absolute lymphocyte count ≥1000/µL Platelets ≥ 100,000/µL ( ≥ 50,000/µL patient hematologic malignancy ) Total bilirubin within normal institutional limit AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time institutional ULN Serum triglycerides ≤ 500 mg/dl Creatinine within normal institutional limit OR Creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Able understand willing sign write informed consent document . Chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Receiving investigational agent . Uncontrolled brain metastasis malignancy . History allergic reaction attribute compound similar chemical biologic composition rapamycin . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Severe immunodeficient state ( judged treat physician ) Pregnancy ( breastfeed must discontinue ) HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction rapamycin . Concurrent use cyclosporine , tacrolimus , rifampin , terfenadine , astemizole , cisapride , rosiglitazone pioglitazone due possible interaction study drug . Ketoconazole take within 2 hour antacid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>